#Cmet Testing

Watch Reels videos about Cmet Testing from people all over the world.

Watch anonymously without logging in.

Related Searches

cmet

Trending Reels

(12)
#Cmet Testing Reel by @personalis_inc - Listen in as Olga Alexeeva, Director at Personalis, presents NEW ASCO 2025 data on ctDNA-based immunotherapy monitoring in advanced malignancies, expl
173
PE
@personalis_inc
Listen in as Olga Alexeeva, Director at Personalis, presents NEW ASCO 2025 data on ctDNA-based immunotherapy monitoring in advanced malignancies, exploring the predictive value of circulating tumor DNA kinetics for treatment response and clinical outcomes. In this retrospective analysis of a 39-patient cohort with advanced cancers and median ~7 months of follow up, ctDNA dynamics correlated with patient outcomes and preceded results on imaging. During immunotherapy treatment monitoring: Patients with ctDNA clearance (mCR - molecular complete response) showed 1-year overall survival (OS) rate of 100% vs 52% in non-mCR group. Patients with molecular response (mR) defined as 50% or greater decrease in ctDNA during treatment from first timepoint to ~23 days later exhibited improved 1-year progression-free survival (PFS) rate of 90% vs 15% in patients without mR. In collaboration with UC San Diego Moores Cancer Center. Nishizaki, Daisuke, et al. (2025, June). Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy success in advanced cancer. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, United States.
#Cmet Testing Reel by @iylononcology - ๐—ฅ๐—ผ๐—น๐—ฒ ๐—ผ๐—ณ ๐—–๐—š๐—ฃ ๐—ถ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐—ฐ๐—ถ๐—ป๐—ด ๐—ฃ๐—ฟ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† ๐—ถ๐—ป ๐—บ๐—ฒ๐˜๐—ฎ๐˜€๐˜๐—ฎ๐˜๐—ถ๐—ฐ ๐—ฐ๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ๐˜€. Precision oncology has adv
111
IY
@iylononcology
๐—ฅ๐—ผ๐—น๐—ฒ ๐—ผ๐—ณ ๐—–๐—š๐—ฃ ๐—ถ๐—ป๐—ณ๐—น๐˜‚๐—ฒ๐—ป๐—ฐ๐—ถ๐—ป๐—ด ๐—ฃ๐—ฟ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† ๐—ถ๐—ป ๐—บ๐—ฒ๐˜๐—ฎ๐˜€๐˜๐—ฎ๐˜๐—ถ๐—ฐ ๐—ฐ๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ๐˜€. Precision oncology has advanced quickly in recent years, offering new ways to match cancer treatments to the specific genetic changes in a personโ€™s tumor. Researchers looked at real-world data from patients with advanced (metastatic) solid cancers who underwent comprehensive genomic profiling (CGP), a detailed test that analyzes many cancer-related genes at once. They found that treatment decisions guided by genomic testing may be linked to better outcomes in routine clinical practice. The nationwide genomic cancer registry showed how collecting and organizing this type of data could help improve the future implementation of precision oncology in healthcare systems. The role of CGP influencing Precision Oncology in metastatic cancers is explained in the following video link. https://youtube.com/shorts/bhZfWEAPfoE ๐˜ˆ๐˜ต ๐˜๐˜บ๐˜ญ๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ (www.iylon.com), ๐˜ธ๐˜ฆ ๐˜ฉ๐˜ข๐˜ณ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜จ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ต๐˜ช๐˜ค ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ท๐˜ช๐˜ฅ๐˜ฆ ๐˜ฑ๐˜ฆ๐˜ณ๐˜ด๐˜ฐ๐˜ฏ๐˜ข๐˜ญ๐˜ช๐˜ป๐˜ฆ๐˜ฅ, ๐˜ฆ๐˜ท๐˜ช๐˜ฅ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด, ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ๐˜ช๐˜ฏ๐˜จ ๐˜จ๐˜ถ๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ, ๐˜ง๐˜ฐ๐˜ณ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฅ๐˜ฐ๐˜ด๐˜ฆ, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ช๐˜ฎ๐˜ฆ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ข๐˜ช๐˜ฎ๐˜ฆ๐˜ฅ ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ข๐˜ณ๐˜จ๐˜ฆ๐˜ต. @senduraimani @jtarantino73
#Cmet Testing Reel by @iylononcology - ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐Ž๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ: ๐†๐ž๐ง๐จ๐ฆ๐ž ๐„๐๐ข๐ญ๐ž๐ ๐‚๐€๐‘-๐“ ๐‚๐ž๐ฅ๐ฅ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ฒ. CAR-T cell therapy is an advanced type of cancer tr
47
IY
@iylononcology
๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐Ž๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ: ๐†๐ž๐ง๐จ๐ฆ๐ž ๐„๐๐ข๐ญ๐ž๐ ๐‚๐€๐‘-๐“ ๐‚๐ž๐ฅ๐ฅ ๐“๐ก๐ž๐ซ๐š๐ฉ๐ฒ. CAR-T cell therapy is an advanced type of cancer treatment that uses a patientโ€™s own immune cells (T cells) and reprograms them to recognize and attack cancer. A newer approach, called universal allogeneic CAR-T therapy, uses immune cells from healthy donors instead of the patient, creating an โ€œoff-the-shelfโ€ treatment that could be produced faster, more consistently, and at lower cost. While this approach is very promising and early clinical trial results are encouraging, there are still major safety and technical challenges, including immune reactions such as graft-versus-host disease, rejection of donor cells by the patientโ€™s immune system, unintended genetic changes, and difficulties in scaling up manufacturing. To overcome these issues, scientists are using powerful gene-editing technologies such as CRISPR and other advanced editing tools to modify donor cells more safely and effectively. Precision Oncology with Genome-edited allogeneic CAR-T cells is explained in the following video link. https://youtube.com/shorts/FEUGStPfGzU ๐˜ˆ๐˜ต ๐˜๐˜บ๐˜ญ๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ (www.iylon.com), ๐˜ธ๐˜ฆ ๐˜ฉ๐˜ข๐˜ณ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜จ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ต๐˜ช๐˜ค ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ท๐˜ช๐˜ฅ๐˜ฆ ๐˜ฑ๐˜ฆ๐˜ณ๐˜ด๐˜ฐ๐˜ฏ๐˜ข๐˜ญ๐˜ช๐˜ป๐˜ฆ๐˜ฅ, ๐˜ฆ๐˜ท๐˜ช๐˜ฅ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด, ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ๐˜ช๐˜ฏ๐˜จ ๐˜จ๐˜ถ๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ, ๐˜ง๐˜ฐ๐˜ณ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฅ๐˜ฐ๐˜ด๐˜ฆ, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ช๐˜ฎ๐˜ฆ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ข๐˜ช๐˜ฎ๐˜ฆ๐˜ฅ ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ข๐˜ณ๐˜จ๐˜ฆ๐˜ต. @senduraimani @jtarantino73
#Cmet Testing Reel by @oncology_awards - Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.#ResearchAwards #academicawards Gain-of-function variants in NOTCH4 alter
108
ON
@oncology_awards
Gain of function NOTCH4 variants disrupt angiogenesis in systemic sclerosis.#ResearchAwards #academicawards Gain-of-function variants in NOTCH4 alter endothelial signaling, leading to abnormal vascular development in systemic sclerosis. Enhanced NOTCH4 activity impairs angiogenic balance, promotes vascular instability, and contributes to fibrosis through dysregulated endothelialโ€“mesenchymal interactions. These findings highlight NOTCH4 as a key molecular driver of vasculopathy and suggest that targeting aberrant NOTCH signaling may offer new therapeutic strategies for disease management and outcomes. International Research Awards on Oncology and Cancer Research Visit Our Website๐ŸŒ : oncology.pencis.com Nominate Now ๐Ÿ‘‰๐Ÿป: https://oncology.pencis.com/awards-nominations/... contact us ๐Ÿ“ง : oncologysupport@pencis.com #HepatitisB #HBVCure #GeneTherapy #TALEN #LipidNanoparticles #mRNATherapy #AntiviralResearch #ViralEradication #BiotechBreakthrough #LNPDelivery #GeneEditing #PrecisionMedicine #HBVResearch #CRISPRvsTALEN #InfectiousDisease #TherapeuticmRNA #NextGenMedicine #Pencis #PencisOncology #PencisAwards #FunctionalCure #LiverHealth #GenomeEditing #MedicalInnovation #hbvtreatment Get Connected Here ==================================== Youtube: https://www.youtube.com/@CancerResearch98 Twitter: https://x.com/Oncology_Awards Instagram: https://www.instagram.com/oncology_awards/ Pinterest: https://www.pinterest.com/Oncology_Awards/
#Cmet Testing Reel by @neogenomicslaboratories - Neo Comprehensiveยฎ - Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping cli
134
NE
@neogenomicslaboratories
Neo Comprehensiveยฎ โ€“ Myeloid Disorders, a CGP NGS assay, delivers clear and precise results for myeloid disorders, including MDS and CMML, helping clinicians make confident decisions. neogenomics.com/providers/test/NTG-MDSX-02BX/neo-comprehensive-myeloid-disorders #NeoGenomics #CancerTesting #OncologyInsights
#Cmet Testing Reel by @onclive - ๐Ÿ“นAntonio Ocejo, MD, describes findings from a study of outcomes with ipilimumab plus nivolumab in ccRCC according to patient age that were presented
241
ON
@onclive
๐Ÿ“นAntonio Ocejo, MD, describes findings from a study of outcomes with ipilimumab plus nivolumab in ccRCC according to patient age that were presented during the 2026 Genitourinary Cancers Symposium. #GU26 #ASCOGU2026 #oncology #RCC #kcsm
#Cmet Testing Reel by @iylononcology - ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐Ž๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ: ๐’๐ข๐ง๐ ๐ฅ๐ž-๐œ๐ž๐ฅ๐ฅ ๐ฆ๐ฎ๐ฅ๐ญ๐ข-๐จ๐ฆ๐ข๐œ๐ฌ. In this paper "Single-cell multi-omics in cancer immunotherapy: fro
149
IY
@iylononcology
๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐Ž๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ: ๐’๐ข๐ง๐ ๐ฅ๐ž-๐œ๐ž๐ฅ๐ฅ ๐ฆ๐ฎ๐ฅ๐ญ๐ข-๐จ๐ฆ๐ข๐œ๐ฌ. In this paper โ€œSingle-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatmentโ€, Dr. Furong Zeng and team summarize the recent advances in Precision Oncology with Single-cell multi-omics. This paper is freely available at the following URL (https://doi.org/10.1186/s12943-025-02426-3). Cancer immunotherapy has transformed cancer care, but treating cancer remains difficult because tumors are highly diverse, both between patients and even within the same tumor. New single-cell multi-omics technologies now allow researchers to study individual cancer and immune cells in great detail, revealing how tumors evolve, escape immune attack, and develop treatment resistance. These advances are improving precision oncology by supporting better immunotherapy strategies, earlier detection of minimal residual disease, and discovery of new targets like neoantigens. Precision Oncology with Single-cell multi-omics is explained in the following video link. https://youtube.com/shorts/4GNjTg292XQ ๐˜ˆ๐˜ต ๐˜๐˜บ๐˜ญ๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ (www.iylon.com), ๐˜ธ๐˜ฆ ๐˜ฉ๐˜ข๐˜ณ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜จ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ต๐˜ช๐˜ค ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ท๐˜ช๐˜ฅ๐˜ฆ ๐˜ฑ๐˜ฆ๐˜ณ๐˜ด๐˜ฐ๐˜ฏ๐˜ข๐˜ญ๐˜ช๐˜ป๐˜ฆ๐˜ฅ, ๐˜ฆ๐˜ท๐˜ช๐˜ฅ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด, ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ๐˜ช๐˜ฏ๐˜จ ๐˜จ๐˜ถ๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ, ๐˜ง๐˜ฐ๐˜ณ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฅ๐˜ฐ๐˜ด๐˜ฆ, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ช๐˜ฎ๐˜ฆ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ข๐˜ช๐˜ฎ๐˜ฆ๐˜ฅ ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ข๐˜ณ๐˜จ๐˜ฆ๐˜ต. @senduraimani @jtarantino73
#Cmet Testing Reel by @iylononcology - ๐— ๐—ง๐—”๐—ฃ: ๐—ฃ๐—ฟ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† ๐—ถ๐—ป ๐—ก๐—ฆ๐—–๐—Ÿ๐—–. Researchers have found that losing a protein called MTAP in lung cancer may help pred
89
IY
@iylononcology
๐— ๐—ง๐—”๐—ฃ: ๐—ฃ๐—ฟ๐—ฒ๐—ฐ๐—ถ๐˜€๐—ถ๐—ผ๐—ป ๐—ข๐—ป๐—ฐ๐—ผ๐—น๐—ผ๐—ด๐˜† ๐—ถ๐—ป ๐—ก๐—ฆ๐—–๐—Ÿ๐—–. Researchers have found that losing a protein called MTAP in lung cancer may help predict how well certain treatments will work. Specifically, MTAP loss may indicate that a patient could respond better to a newer type of drug called PRMT5 inhibitors but respond worse to immunotherapy. In this study, they discovered that CDKN2A loss was not a dependable indicator, many tumors with MTAP loss did not show CDKN2A loss, and some tumors with CDKN2A loss did not actually lose MTAP. Overall, the study suggests that direct MTAP testing using IHC is more accurate than relying on genetic panel testing, and that CDKN2A loss alone is not a reliable substitute for identifying MTAP loss in lung cancer. The role of MTAP expression influencing Precision Oncology in NSCLC is explained in the following video link. https://youtube.com/shorts/y7OopuCUTlA. ๐˜ˆ๐˜ต ๐˜๐˜บ๐˜ญ๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ (www.iylon.com), ๐˜ธ๐˜ฆ ๐˜ฉ๐˜ข๐˜ณ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜จ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ต๐˜ช๐˜ค ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ท๐˜ช๐˜ฅ๐˜ฆ ๐˜ฑ๐˜ฆ๐˜ณ๐˜ด๐˜ฐ๐˜ฏ๐˜ข๐˜ญ๐˜ช๐˜ป๐˜ฆ๐˜ฅ, ๐˜ฆ๐˜ท๐˜ช๐˜ฅ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด, ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ๐˜ช๐˜ฏ๐˜จ ๐˜จ๐˜ถ๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ, ๐˜ง๐˜ฐ๐˜ณ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฅ๐˜ฐ๐˜ด๐˜ฆ, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ช๐˜ฎ๐˜ฆ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ข๐˜ช๐˜ฎ๐˜ฆ๐˜ฅ ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ข๐˜ณ๐˜จ๐˜ฆ๐˜ต. @senduraimani @jtarantino73
#Cmet Testing Reel by @neo7bioscience - Why does biology shift long before a tumor even appears on a scan? ๐Ÿง Understanding the "molecular command level" is the key to the next generation o
3.0K
NE
@neo7bioscience
Why does biology shift long before a tumor even appears on a scan? ๐Ÿง Understanding the โ€œmolecular command levelโ€ is the key to the next generation of cancer treatment. Get the full story on how personalized peptides are leading the way. Unpack the full article at the link in our bio! Biology first. Precision always. ๐Ÿ”ฌ NEO7 Bioscience and the McCullough Foundation are moving beyond reactive oncology. By measuring the unique genome of every patient, we create sequence-specific peptides designed to restore immune recognition and destabilize tumor survival. Send this to someone who needs to see the future of oncology! ๐Ÿš€ #PrecisionOncology #NEO7Bioscience #CancerResearch #PersonalizedMedicine #HealthInnovation MolecularCommand Biotech FutureOfMedicine
#Cmet Testing Reel by @celemics_official - ๐Ÿงฌ New Blog | ๐—™๐—น๐—ฒ๐˜…๐—ถ๐—ฏ๐—น๐—ฒ ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ ๐—ง๐—ฎ๐—ฟ๐—ด๐—ฒ๐˜ ๐—–๐—ฎ๐—ฝ๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฃ๐—ฎ๐—ป๐—ฒ๐—น๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—š๐—ฒ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—ฃ๐—ฟ๐—ผ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด Cancer research is evol
108
CE
@celemics_official
๐Ÿงฌ New Blog | ๐—™๐—น๐—ฒ๐˜…๐—ถ๐—ฏ๐—น๐—ฒ ๐—–๐—ฎ๐—ป๐—ฐ๐—ฒ๐—ฟ ๐—ง๐—ฎ๐—ฟ๐—ด๐—ฒ๐˜ ๐—–๐—ฎ๐—ฝ๐˜๐˜‚๐—ฟ๐—ฒ ๐—ฃ๐—ฎ๐—ป๐—ฒ๐—น๐˜€ ๐—ณ๐—ผ๐—ฟ ๐—š๐—ฒ๐—ป๐—ผ๐—บ๐—ถ๐—ฐ ๐—ฃ๐—ฟ๐—ผ๐—ณ๐—ถ๐—น๐—ถ๐—ป๐—ด Cancer research is evolving toward comprehensive genomic profiling in the precision oncology era. From hereditary cancer studies to somatic mutation profiling and liquid biopsy analysis, selecting the right panel is critical. Our latest blog introduces the full Celemics Cancer Target Capture line-up including CancerScreen, CancerMaster, OncoRisk, and Liquid Biopsy Panels designed for flexible, scalable, and comprehensive biomarker analysis. #cancergenomic #ngs #targetcapture #liquidbiopsy
#Cmet Testing Reel by @onclive - Watch ๐Ÿ‘€: Kenneth Jin Chang Lim, MBBS, discusses prophylactic dexamethasone mitigating neurotoxicity in multiple myeloma. #Tandem2026 #mmsm #oncology
567
ON
@onclive
Watch ๐Ÿ‘€: Kenneth Jin Chang Lim, MBBS, discusses prophylactic dexamethasone mitigating neurotoxicity in multiple myeloma. #Tandem2026 #mmsm #oncology @ASTCT @CIBMTR
#Cmet Testing Reel by @iylononcology - ๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐จ๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ ๐š๐œ๐ซ๐จ๐ฌ๐ฌ ๐ญ๐ก๐ž ๐š๐ ๐ž๐ฌ: ๐ˆ๐ฆ๐ฉ๐š๐œ๐ญ ๐จ๐ง ๐œ๐ก๐ข๐ฅ๐๐ซ๐ž๐ง, ๐š๐๐จ๐ฅ๐ž๐ฌ๐œ๐ž๐ง๐ญ๐ฌ, ๐š๐ง๐ ๐ฒ๐จ๐ฎ๐ง๐  ๐š๐๐ฎ
139
IY
@iylononcology
๐๐ซ๐ž๐œ๐ข๐ฌ๐ข๐จ๐ง ๐จ๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ ๐š๐œ๐ซ๐จ๐ฌ๐ฌ ๐ญ๐ก๐ž ๐š๐ ๐ž๐ฌ: ๐ˆ๐ฆ๐ฉ๐š๐œ๐ญ ๐จ๐ง ๐œ๐ก๐ข๐ฅ๐๐ซ๐ž๐ง, ๐š๐๐จ๐ฅ๐ž๐ฌ๐œ๐ž๐ง๐ญ๐ฌ, ๐š๐ง๐ ๐ฒ๐จ๐ฎ๐ง๐  ๐š๐๐ฎ๐ฅ๐ญ๐ฌ. Precision oncology is an approach to cancer care that aims to choose treatments based on the unique features of each patient and their tumor, rather than using the same therapy for everyone. Major advances in genetic technology transformed cancer research. New tools, known as next-generation sequencing, made it possible to quickly and affordably analyze the genetic makeup of tumors. This helped doctors and researchers identify the key genetic โ€œdriversโ€ behind different cancers and discover markers that predict whether a patient may benefit from newer immune-based treatments. Precision oncology is being used across different age groups, including children, adolescents, and young adults. The role of Precision Oncology across the ages is explained in the following video link. https://youtu.be/QYbQvzelzq4 ๐˜ˆ๐˜ต ๐˜๐˜บ๐˜ญ๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ฆ๐˜ค๐˜ช๐˜ด๐˜ช๐˜ฐ๐˜ฏ ๐˜–๐˜ฏ๐˜ค๐˜ฐ๐˜ญ๐˜ฐ๐˜จ๐˜บ (www.iylon.com), ๐˜ธ๐˜ฆ ๐˜ฉ๐˜ข๐˜ณ๐˜ฏ๐˜ฆ๐˜ด๐˜ด ๐˜จ๐˜ฆ๐˜ฏ๐˜ฆ๐˜ต๐˜ช๐˜ค ๐˜ช๐˜ฏ๐˜ด๐˜ช๐˜จ๐˜ฉ๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ท๐˜ช๐˜ฅ๐˜ฆ ๐˜ฑ๐˜ฆ๐˜ณ๐˜ด๐˜ฐ๐˜ฏ๐˜ข๐˜ญ๐˜ช๐˜ป๐˜ฆ๐˜ฅ, ๐˜ฆ๐˜ท๐˜ช๐˜ฅ๐˜ฆ๐˜ฏ๐˜ค๐˜ฆ-๐˜ฃ๐˜ข๐˜ด๐˜ฆ๐˜ฅ ๐˜ณ๐˜ฆ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ฅ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด, ๐˜ฉ๐˜ฆ๐˜ญ๐˜ฑ๐˜ช๐˜ฏ๐˜จ ๐˜จ๐˜ถ๐˜ช๐˜ฅ๐˜ฆ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ช๐˜ฏ๐˜ฆ, ๐˜ง๐˜ฐ๐˜ณ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฑ๐˜ข๐˜ต๐˜ช๐˜ฆ๐˜ฏ๐˜ต, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ฅ๐˜ฐ๐˜ด๐˜ฆ, ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ช๐˜ฎ๐˜ฆ, ๐˜ข๐˜ฏ๐˜ฅ ๐˜ข๐˜ช๐˜ฎ๐˜ฆ๐˜ฅ ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ฆ ๐˜ณ๐˜ช๐˜จ๐˜ฉ๐˜ต ๐˜ต๐˜ข๐˜ณ๐˜จ๐˜ฆ๐˜ต. @senduraimani @jtarantino73

โœจ #Cmet Testing Discovery Guide

Instagram hosts thousands of posts under #Cmet Testing, creating one of the platform's most vibrant visual ecosystems. This massive collection represents trending moments, creative expressions, and global conversations happening right now.

The massive #Cmet Testing collection on Instagram features today's most engaging videos. Content from @neo7bioscience, @onclive and @personalis_inc and other creative producers has reached thousands of posts globally. Filter and watch the freshest #Cmet Testing reels instantly.

What's trending in #Cmet Testing? The most watched Reels videos and viral content are featured above. Explore the gallery to discover creative storytelling, popular moments, and content that's capturing millions of views worldwide.

Popular Categories

๐Ÿ“น Video Trends: Discover the latest Reels and viral videos

๐Ÿ“ˆ Hashtag Strategy: Explore trending hashtag options for your content

๐ŸŒŸ Featured Creators: @neo7bioscience, @onclive, @personalis_inc and others leading the community

FAQs About #Cmet Testing

With Pictame, you can browse all #Cmet Testing reels and videos without logging into Instagram. No account required and your activity remains private.

Content Performance Insights

Analysis of 12 reels

โœ… Moderate Competition

๐Ÿ’ก Top performing posts average 989.75 views (2.5x above average). Moderate competition - consistent posting builds momentum.

Post consistently 3-5 times/week at times when your audience is most active

Content Creation Tips & Strategy

๐Ÿ’ก Top performing content gets hundreds of views - focus on engaging first 3 seconds

โœ๏ธ Detailed captions with story work well - average caption length is 1020 characters

๐Ÿ“น High-quality vertical videos (9:16) perform best for #Cmet Testing - use good lighting and clear audio

Popular Searches Related to #Cmet Testing

๐ŸŽฌFor Video Lovers

Cmet Testing ReelsWatch Cmet Testing Videos

๐Ÿ“ˆFor Strategy Seekers

Cmet Testing Trending HashtagsBest Cmet Testing Hashtags

๐ŸŒŸExplore More

Explore Cmet Testing#cmet